Elsevier

Gynecologic Oncology

Volume 121, Issue 3, 1 June 2011, Pages 625-636
Gynecologic Oncology

Review
Multidisciplinary management of malignant ovarian germ cell tumours

https://doi.org/10.1016/j.ygyno.2010.12.351Get rights and content

Abstract

Objectives

Malignant ovarian germ cell tumours (MOGCT) are rare cancers of young women. Limited prospective trials exist from which evidence-based management can be developed. This review summarizes the available literature concerning MOGT in order to provide the clinician with information relevant to their multidisciplinary management.

Methods

MEDLINE was searched between 1966 and 2010 for all publications in English where the studied population included women diagnosed with malignant ovarian germ cell tumours.

Results

The majority of patients can be cured with fertility-preserving surgery with or without combination chemotherapy. Long term survival approaches 100% in early stage disease and is approximately 75% in advanced stage disease. Most studies suggest that the treatment has little, if any, effect on future fertility and limited data suggest that there is no adverse effect on the future quality of life.

Conclusion

MOGCTs are rare tumours of young women the majority of which can be successfully treated with fertility-preserving surgery with or without chemotherapy with preservation of reproductive function. Minimisation of chemotherapy in good prognostic groups and improved treatment in resistant and relapsed MOGCT are important goals for the future. Further studies are needed to quantify the late adverse effects of treatment in long term survivors.

Research Highlights

►Ovarian germ cell tumours are highly curable. ►Treatment options are limited for recurrent and residual tumours. ►Long term results suggest no significant impact on fertility and menstrual function.

Introduction

Malignant ovarian germ cell tumours (MOGCTs) are tumours derived from primitive germ cells of the embryonic gonad. These are highly malignant and rapidly growing tumours with a peak incidence occurring in adolescent and young women. The incidence varies according to geographic areas; the estimated incidence of MOGCT in the USA is 0.41 cases per 100,000 women [1] compared with 0.2 in the UK [2]. MOGCTs account for less than 5% of all ovarian malignancies in the Western countries, whereas they may represent up to 15% of ovarian cancers in Asians and blacks [3].

MOGCTs are broadly classified into two types: dysgerminomas, which are the ovarian counterpart of seminoma and non-dysgerminoma, which consist of a number of subtypes and are the ovarian counterpart of non-seminoma [3]. Since many of the patients present with early stage disease with cure rate approaching 100% and affect young women, multidisciplinary evaluation and treatment are important.

Section snippets

Staging and evaluation

MOGCTs are staged according to the FIGO staging for ovarian cancer. In general, 60 to 70% of MOGCT are stage I, 25–30% stage III, and stage II and IV are rare. This is in striking contrast to epithelial ovarian tumours where 70–75% are stage III and the remainder are equally divided by stages I, II and IV [4].

Principles of surgery

Surgery is the initial treatment of choice. Staging laparotomy follows the principles applied to epithelial ovarian cancer. Since this disease predominantly affects the young females, conservative surgery to preserve fertility is the norm and the minimal surgery is unilateral oophorectomy [26], [27], [28], [29], [30]. Cystectomy may be an adequate surgical approach however larger studies are needed before it can be considered standard. In one series of 8 patients with stage I immature teratoma

Prognostic factors

The most important prognostic factors are histological type and stage. Dysgerminoma has the best prognosis among all histological types with cure rates of > 95% even in advanced disease [69], [70], [71], [72], though with modern chemotherapy even the traditionally poor prognosis histiotypes are achieving good outcomes. Before the era of cisplatin based chemotherapy overall survival for patients with yolk sac tumours at 3 years was 13% [73]. With modern BEP regimens, a recent retrospective series

Follow-up

90% of relapses in MOGCT occur within 2 years. Dysgerminomas may recur late, up to 10 years after primary treatment. Follow up by serial measurement of tumour markers and radiological and clinical assessment every 3 monthly for the first 2 years, six monthly for three years, then annually to five years is recommended for non-dysgerminomatous tumours, and to 10 years for dysgerminoma. AFP and ß-HCG are routinely measured for all patients even if not initially raised since occasionally recurrences

Management of relapsed and refractory tumours

Approximately 20% of advanced germ cell tumours will be resistant to treatment or relapse at a later stage [57]. For patients failing optimal primary treatment, either with persistent, progressive or relapsed disease, the outlook is poor with long germ survival of 10% [62].

Evidence to guide the management of patients with recurrent ovarian germ cell tumours is sparse and largely extrapolated from experience with testicular cancer. There are some prospective studies in MOGCT [40], [79] and some

Fertility and teratogenesis

Most studies suggest no adverse effect on fertility or teratogenesity following fertility-preserving surgery and chemotherapy for MOGT [28], [29], [30], [86], [118]. In a study of 40 patients who had conservative surgery, 27 (68%) retained regular menses and 83% were having regular menses at the time of follow-up. Sixteen patients attempted to become pregnant, 12 did so and had 22 healthy children over time. No increase in congenital abnormality was reported in the offspring [119]. In the GOG

Conclusion

MOGCTs are rare tumours, the majority of which occur at a critical point in the development of young women. Most patients can be successfully treated with fertility-preserving surgery with or without chemotherapy with preservation of reproductive function. Better risk stratification to reduce treatment in good prognostic groups and improve treatment in poor prognostic or relapsed patients would be of benefit.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

References (152)

  • T.P. Cotter et al.

    Elevated serum angiotensin converting enzyme levels in metastatic ovarian dysgerminoma

    Respir Med

    (Apr 1997)
  • M. Suzuki et al.

    Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary

    Gynecol Oncol

    (Jan 1998)
  • K. Tewari et al.

    Malignant germ cell tumors of the ovary

    Obstet Gynecol

    (Jan 2000)
  • M.E. Beiner et al.

    Cystectomy for immature teratoma of the ovary

    Gynecol Oncol

    (May 2004)
  • S.C. Mengshol et al.

    Gliomatosis peritonei and teratomatous implant with carcinomatous transformation presenting 54 years following oophorectomy for dermoid cyst

    Gynecol Oncol

    (Jan 2004)
  • S.D. Williams et al.

    Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience

    Gynecol Oncol

    (Mar 1994)
  • D.M. Gershenson

    The obsolescence of second-look laparotomy in the management of malignant ovarian germ cell tumors

    Gynecol Oncol

    (Mar 1994)
  • S.J. Buskirk et al.

    Ovarian dysgerminoma: a retrospective analysis of results of treatment, sites of treatment failure, and radiosensitivity

    Mayo Clin Proc

    (Dec 1987)
  • M.A. Dimopoulos et al.

    Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study

    Gynecol Oncol

    (Dec 2004)
  • S.D. Williams et al.

    Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group

    Gynecol Oncol

    (Dec 2004)
  • R.T. Oliver et al.

    Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial

    Lancet

    (Jul 23–29 2005)
  • C.H. Lai et al.

    Outcome and prognostic factors in ovarian germ cell malignancies

    Gynecol Oncol

    (Mar 2005)
  • D. Billmire et al.

    Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study

    J Pediatr Surg

    (Mar 2004)
  • J.R. Germa et al.

    Malignant ovarian germ cell tumors: the experience at the Hospital de la Santa Creu i Sant Pau

    Gynecol Oncol

    (May 1992)
  • J.M. O'Sullivan et al.

    Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours

    Ann Oncol

    (Jan 2003)
  • M.S. Zaghloul et al.

    Dysgerminoma of the ovary: good prognosis even in advanced stages

    Int J Radiat Oncol Biol Phys

    (1992)
  • T. de La Motte Rouge et al.

    Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases

    Eur J Cancer

    (Jan 2011)
  • A. Nawa et al.

    Prognostic factors of patients with yolk sac tumors of the ovary

    Am J Obstet Gynecol

    (May 2001)
  • S. Culine et al.

    A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary

    Gynecol Oncol

    (Jul 1994)
  • M.A. Dimopoulos et al.

    Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study

    Gynecol Oncol

    (Jul 1998)
  • M.M. Cheung et al.

    Experience with the management of ovarian germ cell tumors in Chinese patients

    Gynecol Oncol

    (Mar 1994)
  • P.E. Schwartz et al.

    Ovarian germ cell malignancies: the Yale University experience

    Gynecol Oncol

    (Apr 1992)
  • A. Munkarah et al.

    Salvage surgery for chemorefractory ovarian germ cell tumors

    Gynecol Oncol

    (Nov 1994)
  • J. Li et al.

    Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients

    Gynecol Oncol

    (Jun 2007)
  • M. Bower et al.

    Chemotherapy for ovarian germ cell tumours

    Eur J Cancer

    (Apr 1996)
  • S. Culine et al.

    Salvage chemotherapy in non-dysgerminomatous germ cell tumours of the ovary

    Eur J Cancer

    (Oct 1995)
  • L.C. Wong et al.

    Etoposide combination chemotherapy in refractory ovarian malignant germ cell tumor

    Gynecol Oncol

    (Nov 1990)
  • J.L. Pico et al.

    A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours

    Ann Oncol

    (Jul 2005)
  • C. Westhoff et al.

    Benign ovarian teratomas: a population-based case-control study

    Br J Cancer

    (Jul 1988)
  • J.S. Berek et al.

    Nonepithelial ovarian and fallopian tube cancers

  • N.R. Abu-Rustum et al.

    Management of malignant germ cell tumors of the ovary

    Semin Oncol

    (Apr 1998)
  • E.S. Newlands et al.

    Tumour markers and POMB/ACE chemotherapy in the management of ovarian germ cell tumours (GCTs)

    Int J Biol Markers

    (Jul–Sep 1988)
  • M.S. Motawy et al.

    Serum AFP, hCG and CEA in the management of patients with testicular, ovarian and extragonadal germ cell tumors

    Int J Biol Markers

    (Apr–Jun 1992)
  • T. Ueno et al.

    Spectrum of germ cell tumors: from head to toe

    Radiographics

    (Mar–Apr 2004)
  • H.M. Brammer et al.

    From the archives of the AFIP. Malignant germ cell tumors of the ovary: radiologic-pathologic correlation

    Radiographics

    (Jul 1990)
  • Y. Tanaka et al.

    Gonadal mixed germ cell tumor combined with a large hemangiomatous lesion in a patient with Turner's syndrome and 45, X/46, X, + mar karyotype

    Arch Pathol Lab Med

    (Nov 1994)
  • M.L. Rosado-de-Christenson et al.

    From the archives of the AFIP. Mediastinal germ cell tumors: radiologic and pathologic correlation

    Radiographics

    (Sep 1992)
  • R.G. Levitt et al.

    CT of primary germ-cell tumors of the mediastinum

    AJR Am J Roentgenol

    (Jan 1984)
  • M. De Santis et al.

    2-18fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial

    J Clin Oncol

    (Mar 15 2004)
  • M. de Wit et al.

    18F]-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: first results of the German Multicenter Trial

    J Clin Oncol

    (2005)
  • Cited by (0)

    View full text